Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

被引：2
|
作者：
Tefferi, Ayalew [1 ]
Pardanani, Animesh [1 ]
Gangat, Naseema [1 ]
机构：
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 08期
关键词：
HYDROXYUREA; MUTATIONS; THERAPY; CALRETICULIN; RUXOLITINIB; JAK2(V617F); TRIAL; AGE;
D O I：
10.1002/ajh.27375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1459 / 1461
页数：3
相关论文
共 50 条
  • [1] JAK2V617F allele burden in polycythemia vera: burden of proof
    Moliterno, Alison R.
    Kaizer, Hannah
    Reeves, Brandi N.
    BLOOD, 2023, 141 (16) : 1934 - 1942
  • [2] Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
    Kuriakose, Emil
    Vandris, Katherine
    Wang, Y. Lynn
    Chow, William
    Jones, Amy V.
    Christos, Paul
    Cross, Nicholas C. P.
    Silver, Richard T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 538 - 542
  • [3] Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Edahiro, Yoko
    Sunami, Yoshitaka
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Sato, Eriko
    Ohsaka, Akimichi
    Komatsu, Norio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (02) : 148 - 153
  • [4] Effect of busulfan on JAK2V617F allele burden
    Randi, Maria Luigia
    Santarossa, Claudia
    Peroni, Edoardo
    Cosi, Elisabetta
    Duner, Elena
    Bertozzi, Irene
    Fabris, Fabrizio
    HAEMATOLOGICA, 2014, 99 (03) : E44 - E44
  • [5] Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
    Antonioli, Elisabetta
    Carobbio, Alessandra
    Pieri, Lisa
    Pancrazzi, Alessandro
    Guglielmelli, Paola
    Delaini, Federica
    Ponziani, Vanessa
    Bartalucci, Niccolo
    Tozzi, Lorenzo
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1435 - 1438
  • [6] JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia
    Randi, Maria Luigia
    Ruzzon, Elisabetta
    Tezza, Fabiana
    Scapin, Margherita
    Duner, Elena
    Scandellari, Raffaella
    Fabris, Fabrizio
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 23 (01) : 17 - 21
  • [7] Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
    Vannucchi, Alessandro Maria
    Verstovsek, Srdan
    Guglielmelli, Paola
    Griesshammer, Martin
    Burn, Timothy C.
    Naim, Ahmad
    Paranagama, Dilan
    Marker, Mahtab
    Gadbaw, Brian
    Kiladjian, Jean-Jacques
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1113 - 1120
  • [8] Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
    Swierczek, Sabina I.
    Yoon, Donghoon
    Bellanne-Chantelot, Christine
    Kim, Soo Jin
    Saint-Martin, Cecile
    Delhommeau, Francois
    Najman, Albert
    Prchal, Josef T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (05): : 775 - 778
  • [9] JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
    Kuriakose, Emil T.
    Gjoni, Stefani
    Wang, Y. Lynn
    Baumann, Ruth
    Jones, Amy V.
    Cross, Nicholas C. P.
    Silver, Richard T.
    HAEMATOLOGICA, 2013, 98 (11) : E135 - E137
  • [10] Hydroxyurea dose impacts hematologic parameters In polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden
    Zalcberg, Ilana Renault
    Ayres-Silva, Jackme
    de Azevedo, Alexandre Mello
    Solza, Cristiana
    Daumas, Adelmo
    Bonamino, Martin
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03):
12345